arrow
L

Luo Yang

senior department of infectious diseases
H指数:15
被引数:900

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia

更正:升高的IL-17A水平与肝细胞癌高胆红素血症患者接受免疫检查点抑制剂联合靶向治疗后较差的总生存期相关

2026-04-270
OAAI
Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia

高水平的IL-17A与合并高胆红素血症的肝细胞癌患者在接受免疫检查点抑制剂联合靶向治疗后较差的总生存期相关。

2026-04-070
OAAI
Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study

卡度尼利单抗,一种PD-1/CTLA-4双特异性抗体在不可切除肝癌中的研究:一项真实世界研究

2025-04-280
OA
Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study

PD-1抑制剂联合酪氨酸激酶抑制剂组合疗法在合并高胆红素血症的晚期肝细胞癌患者中的安全性与有效性:一项回顾性队列研究

2025-03-110
OA